We can’t show the full text here under this license. Use the link below to read it at the source.
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Chronic Kidney Disease and SGLT2 Inhibitors: Changes in Treatment Options
AI simplified
Abstract
Sodium-glucose cotransporter 2 () inhibitors may significantly reduce the risk of (CKD) progression and all-cause mortality.
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were the only agents shown to reduce CKD progression over the past 20 years.
- Both drug classes lack evidence for reducing all-cause mortality in CKD patients.
- SGLT2 inhibitors have shown promise in managing CKD, supported by results from key trials like CREDENCE and DAPA-CKD.
- Canagliflozin reduced CKD progression in patients with type 2 diabetes, while dapagliflozin demonstrated similar benefits in patients with or without diabetes.
- DAPA-CKD is notable for being the first trial to show a reduced risk of all-cause mortality in CKD patients.
AI simplified
Key numbers
30%
Risk Reduction with Canagliflozin
Reduction in risk of ESKD, doubling of serum creatinine, or renal or cardiovascular death.
39%
Risk Reduction with Dapagliflozin
Reduction in sustained 50% or more decline in eGFR, ESKD, or renal or cardiovascular death.
15% of adults
Prevalence of
Estimated prevalence of in the USA.